INTRODUCTION
Liver cirrhosis is the common end stage of chronic liver diseases and significantly reduces the life quality and expectancy [1, 2] . The most common causes of chronic liver injury include hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, alcohol, non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, as well as other rare conditions [3] . The natural course of liver diseases varies considerably between individual patients [3] .
This inter-individual variability might be related to different confounding factors, including clinical, environmental, and host factors [4] . The known risk factors for progression of liver injury such as age, gender, alcohol consumption, and obesity cannot explain all the clinically evident differences observed in patients [5] .
The advent of new genomic technologies and the decreased costs of genotyping have been followed by multiple studies that point to the importance of genetic predisposition in different liver diseases [6] . To date, several gene polymorphisms have been linked with the progression of liver fibrosis and the development of liver cirrhosis [6] . Initially, Huang et al. (2007) developed a cirrhosis risk score signature containing seven predictive single nucleotide polymorphisms (SNPs) that were associated with the risk for HCV cirrhosis [7] . A later, large scale genome-wide associated study (GWAS) demonstrated J Gastrointestin Liver Dis, March 2017 Vol. 26 No 1: 37-43 that the patatin-like phospholipase domain containing 3 (PNPLA3) gene polymorphism rs738409 was associated with NAFLD [8] and affects the activities of liver enzymes in plasma [9] . The PNPLA3 gene polymorphism rs738409 was also shown to accelerate liver fibrosis progression rate in HCV-infected patients [10] and contribute to the development of alcoholic liver cirrhosis [11] . Further genetic association studies discovered two other loci harboring RNF7, which is also known as SAG (sensitive to apoptosis gene), and proto-oncogene tyrosine-protein kinase MER (MERTK), which may influence the development of fibrosis in chronic hepatitis C [12] . A metaanalysis of GWAS results on the soluble transferrin receptor (sTfR) and ferritin reported a novel association between sTfR and the variation in the proprotein convertase 7 (PCSK7) gene and the iron overload [13] . These polymorphisms were extensively studied by Stickel et al. [14] , who showed that the PCSK7 variant rs236918 was a risk factor for the development of cirrhosis in hereditary hemochromatosis (HH).
The aforementioned genetic variants have been shown to affect the development of liver fibrosis or cirrhosis. However, the relevance of these results for different populations remains to be established. Due to a large number of analyzed genetic variants, the validation in independent cohorts of patients from different populations of the GWAS results is necessary. In this study, we aimed to evaluate the association between four SNPs reported in GWAS (MERTK rs4374383, PCSK7 rs236918, PNPLA3 rs738409, RNF7 rs16851720) and the risk of liver fibrosis and cirrhosis.
METHODS

Patients
A number of 969 individuals were included in the study: 498 controls, 317 patients with liver cirrhosis, and 154 patients with liver fibrosis. The consecutive patients with liver cirrhosis and liver fibrosis were recruited at the Department of Gastroenterology, Lithuanian University of Health Sciences Hospital, during the period 2012-2015. The diagnosis and etiology of liver cirrhosis were confirmed by laboratory tests, clinical features, liver biopsy, and radiological imaging. The patients in liver fibrosis group underwent percutaneous liver biopsy and were included in the study if stage 1 to 3 fibrosis was documented by histological evaluation using METAVIR score [15] . Control samples came from our previous genotyping study on the prevalence of HFE mutations in the Lithuanian population and included 498 voluntary, unrelated Lithuanian blood donors [16] . The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki (6th revision, 2008). The study was approved by the Ethics Committee of the Lithuanian University of Health Sciences (Protocol Nr. BE-2-10). All patients and controls gave their informed consent to take part in this study.
Genotyping
Genomic DNA from samples was isolated from whole blood mononuclear cells using a salting-out method and stored at −20°C until analysis. PNPLA3 C>G (rs738409), RNF7 A>C (rs16851720), MERTK A>G (rs4374383) and PCSK7 C>G (rs236918) SNPs were genotyped by real-time PCR (RT-PCR), using TaqMan® allelic discrimination assays with a 7500TM Fast real-time PCR system (Life Technologies, Carlsbad, California, USA).
Statistical analysis
The distribution of the PNPLA3, RNF7, MERTK and PCSK7 genotypes in cases and controls was examined for consistency with the Hardy-Weinberg equilibrium (HWE). Allele frequencies were compared between cases and controls by Pearson's goodness-of-fit χ 2 test. Associations between control and cases groups with SNP alleles and genotypes were calculated using logistic regression analysis with adjustment for age and sex. The relative risks for mutations were estimated using allelic, genotypic, recessive and dominant models. Recessive and dominant models led to a comparison between homozygous vs. wild type + heterozygous and heterozygous + homozygous vs. wild type carriers. Adjusted odds ratios (aORs) and 95% confidence intervals (CI) are reported. A p value of 0.05 was defined to be statistically significant. Age is shown as a mean with a standard deviation, and was compared using analysis of variance (ANOVA). Gender distributions were compared using the χ 2 tests. Statistical analysis of the genotyping data was performed using PLINK software version 1.07 [17] . Table I summarizes the characteristics of study participants. The most common causes of liver cirrhosis were chronic HCV infection and alcohol. The distribution of Child-Pugh classes A, B and C in the cirrhotic group was 31.2%, 48.0% and 20.8%, respectively. The most common cause of liver injury in the fibrosis group was HCV infection. The subjects differed in age and sex between the study groups. Men were predominant in the control and liver fibrosis groups and accounted for 63.9% and 61.7%, respectively. Patients with liver cirrhosis were significantly (P<0.001) older than those with liver fibrosis and control groups. To eliminate the potential bias of differences in age and sex distribution among the groups, these parameters were included as covariates in further logistic regression analysis.
RESULTS
Characteristics of study participants
Hardy-Weinberg equilibrium
The observed genotype frequencies for all four SNPs included in the study were concordant with the HardyWeinberg equilibrium (rs738409, P=0.5369; rs16851720, P=0.7885; rs4374383, P=0.1752; rs236918; P=0.3483). ; aOR: 3.02, CI: 1.45-6.28; P=0.003, respectively) inheritance models (Table II) .
Association of PNPLA3, RNF7, MERTK and PCSK7 SNPs with liver fibrosis and cirrhosis
The RNF7 rs16851720 CC genotype was protective against liver damage in the combined liver cirrhosis and fibrosis group (aOR: 0.33; CI: 0.13-0.80, P=0.014) and the liver cirrhosis group (aOR: 0.26, CI: 0.08-0.80, P=0.019). Similarly, considering recessive inheritance, the genotype CC was less frequent in both liver cirrhosis and liver fibrosis (aOR: 0.34, CI: 0.14-0.82, P=0.016) and in patients with liver cirrhosis (aOR: 0.26; CI: 0.09-0.81, P=0.020). The distributions of alleles and genotypes of MERKT and PCSK7 SNPs were similar between the control, liver fibrosis and cirrhosis groups. MERKT rs4374383 was neither associated with the risk of developing liver fibrosis (Table II) .
Association of PNPLA3, RNF7, MERTK and PCSK7 SNPs with HCV and non-HCV liver cirrhosis
Since a large proportion of patients within the cirrhosis group were HCV patients, we carried out a sub-analysis for the risk of developing liver cirrhosis in HCV and non-HCV patients (Table III) . PNPLA3 SNP was associated with higher risk of both HCV and non-HCV induced liver cirrhosis. The ; Table III ). The RNF7 rs16851720 CC genotype was less frequent than AA genotype in non-HCV cirrhosis group if compared to the control group (aOR: 0.28, CI: 0.08-1.00, P=0.050). Interestingly, frequencies of RNF7 rs16851720 genotypes and alleles in HCV cirrhosis group did not differ from the controls. However, the potential association could be blunted by the relatively small number of individuals within this group. The rs236918 (PCSK7) and rs4374383 (MERTK) were not linked with the risk of developing liver cirrhosis in HCV or non-HCV patients (Table III) .
Association analysis of the effect of the combined PNPLA3 and RNF7 SNPs for development of HCV liver fibrosis and liver cirrhosis (Table IV) .
DISCUSSION
In the present study, we aimed to replicate in our population the associations between key PNPLA3, RNF7, MERTK and PCSK7 gene polymorphisms and the risk of liver fibrosis and cirrhosis that have been reported in recent GWAS. We have shown that PNPLA3 rs738409 is associated with the risk of developing both liver fibrosis and cirrhosis and that RNF7 rs16851720 is associated with liver cirrhosis. Our study also revealed that PNPLA3 rs738409 is a risk factor for developing liver cirrhosis in both HCV and non-HCV patients. To date, this is the first study that has demonstrated that PNPLA3 rs738409 confers an increased risk of liver fibrosis and cirrhosis in an Eastern European population. To our knowledge, replication analysis of the association between RNF7 rs16851720 and liver cirrhosis has also not been reported previously. Furthermore, replication studies on MERTK rs4374383 and PCSK7 rs236918 in patients with liver diseases are scarce.
The major finding in our cohort of patients is that PNPLA3 rs738409 is linked to liver fibrosis and cirrhosis, confirming an association that has been reported in distinct ethnic groups [8, 11, 18, 19] . We confirmed this association both in HCV and non-HCV cirrhosis groups. This frequent PNPLA3 variant is also associated with serum ALT activities already at a young age [20] and is a prominent risk factor for HCC [21] . The highly significant differences and odds ratios observed for liver fibrosis and cirrhosis point to the importance of this genetic variant for liver damage. The exact mechanisms on how PNPLA3 contributes to fibrogenesis are still under investigation [22, 23] . It is known that PNPLA3 as a lipase is responsible for retinyl-palmitate hydrolysis in the hepatic stellate cells in humans [24] . Furthermore, the same group has recently shown that PNPLA3-mediated retinol release may protect against liver fibrosis [25] . Other studies have shown that the PNPLA3 I148M variant is relevant for the retinyl-palmitate content in human liver [26] and influences circulating retinol levels in adults [27] . A recent elegant study in mice has shown that PNPLA3 I148M knock-in mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis [28] . All of these studies start to unveil the role of PNPLA3 in liver damage at a molecular level and might suggest important targets for future therapies.
A large GWAS has shown that a locus in the RNF7 gene is associated with the development of liver fibrosis in chronic hepatitis C [12] . The study reported that in the combined cohort of 2,342 HCV-infected patients rs16851720 was associated with fibrosis progression. RNF7 encodes an antioxidant that protects against apoptosis [29] . The results of our study support these findings, because the rs16851720 AA genotype conferred an increased risk of liver cirrhosis. We did not observe differences in the genotype frequencies between controls and patients with liver fibrosis for the RNF7 rs16851720. To our knowledge, no other studies have addressed the role of this gene polymorphism beyond the published GWAS [12] . In order to evaluate the combined effect of PNPLA3 and RNF7 SNPs genotypes for the risk of HCV fibrosis or cirrhosis, we performed an additional analysis. Interestingly, the combined GG PNPLA3 CA RNF7 genotype revealed a very high OR of 5.98 (p=0.006) for HCV related fibrosis. However, the subgroups of patients within this analysis were not very large and these findings need to be validated in larger groups of patients.
A recent meta-analysis of GWAS results revealed a novel association between the variation in PCSK7 gene and iron overload [13] . Stickel et al. [14] reported that the PCSK7 variant rs236918 was a risk factor for the development of cirrhosis in HH patients homozygous for the HFE p.C282Y mutation. Hypothesizing that this SNP might contribute to the development of liver damage in other chronic liver diseases, we genotyped PCSK7 rs236918 in our cohort of patients with liver fibrosis and cirrhosis. Based on our findings, alleles and genotypes of this SNP were distributed equally between the study groups. A recent Italian study has confirmed that the PCSK7 rs236918 C allele represents a risk factor for cirrhosis development in Italian patients with HH [30] . Interestingly, during the 6-month weight-loss study, the PCSK7 rs236918 G allele was significantly associated with the decrease of fasting insulin levels in the high-dietary carbohydrate group [31] . Further, large scale studies are required to evaluate whether the PCSK7 SNP affects the development of liver cirrhosis in other patients than HH.
In our study, the MERTK rs4374383 SNP alleles and genotypes were distributed equally between the control, liver fibrosis and cirrhosis groups. The initial association between MERTK rs4374383 and development of fibrosis in chronic HCV disease was observed in a GWAS; in this study, the association was observed only in a sub-group of HCV patients who received blood transfusions [12] . Later, the MERTK SNP significantly added risk to accelerated fibrosis progression rate in the Swiss Hepatitis C Cohort Study [10] . Interestingly, a recent study also showed that the rs4374383 AA genotype was protective against F2-F4 fibrosis in patients with NAFLD [32] . One of the potential explanations for differences between the previously published data and our results could be linked to the sample size of our patient groups.
Our study has certain limitations that need to be acknowledged. Firstly, the cohort of our cirrhotic patients is heterogeneous with respect to etiology and specific genetic variants might be more important for different types of cirrhosis. In particular, we could not assess the association between SNPs and risk of NAFLD related cirrhosis, because we had only a very few patients with this diagnosis in our study group. We also did not have complete information on alcohol consumption, metabolic syndrome and diabetes status, that might have modified the effects of the analyzed genetic variants. Our cohorts with liver cirrhosis and fibrosis were also not very large and might have been underpowered to detect subtle genetic associations. The groups of patients with different liver function impairment levels were also not very large and this aspect needs to be reassessed in further larger scale studies. Nevertheless, we believe that the results of our study are useful for further metaanalyses in the field. Due to the design of the study we could not include certain other polymorphisms such as the TM6SF2 or MBOAT7 SNPs, which have been recently associated with liver cirrhosis [11, 33] , and this remains a task for further studies.
CONCLUSION
The PNPLA3 rs738409 and RNF7 rs16851720 SNPs were associated with the risk of developing liver fibrosis and liver cirrhosis. These genetic alterations might facilitate progression of liver fibrosis. In our study population, the MERTK rs4374383 and PCSK7 rs236918 SNPs were not linked with the risk of liver fibrosis or liver cirrhosis.
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